fig1

Using cfRNA as a tool to evaluate clinical treatment outcomes in patients with metastatic lung cancers and other tumors

Figure 1. PCR signals of beta-actin from cfRNA (as its cDNA) and from cfDNA in identical aliquots of patients’ plasma. P < 0.001 for the difference in median signal values (Wilcoxon/Kruskal-Wallis rank sums). PCR: Polymerase chain reaction.

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/